# A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

> **NCT02814838** · PHASE2 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 76 (actual)

## Conditions studied

- Diabetes Mellitus, Insulin-Dependent

## Interventions

- **DRUG:** Ladarixin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02814838
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-05-15
- **Final completion:** 2019-05-15
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02814838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02814838, "A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02814838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*